🚀 Thrilled to announce that Arve Capital has invested in R.grid as part of their recent $6.5M seed round led by Fuel Ventures 🚀! Alongside, Morgan Stanley, Ada Ventures, Arāya Ventures, Ascension, Plug and Play Tech Center, and Atomico Angels, among others. R.grid’s AI-powered platforms, Inclusive and TrialEngine, are eliminating back-office bottlenecks in clinical trials, helping researchers save time and resources. This funding will fuel their expansion into the U.S. and Asian markets, making trials faster, more efficient, and patient-centered. We’re excited to be part of their journey to reshape clinical research! Read more here: https://lnkd.in/gQp4fRg7 #ClinicalTrials
Arve Capital
Investment Management
We invest in seed and early stage technology companies in the area of health and well-being.
Info
Arve Capital is the venture capital arm of a German single family office with an investment focus on early-stage technology companies in the area of health and well-being. Based on the entrepreneurial roots in the healthcare sector, Arve Capital is a dedicated long-term partner for passionate founders on their mission to ensure and promote healthy lives.
- Branche
- Investment Management
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Heidelberg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
Orte
-
Primär
Wegbeschreibung
Heidelberg, 69115, DE
Beschäftigte von Arve Capital
Updates
-
We are excited to announce our investment in StratifAI, a groundbreaking company developing multimodal AI models that provide meaningful prognostic insights from histology images and clinical data. Their technology is set to transform oncology by guiding treatment decisions with precision. https://lnkd.in/e-zYG69B One of StratifAI's flagship products, the Breast Cancer Recurrence CDx, uses AI to analyze routine histopathology images, helping clinicians assess cancer recurrence risk and guide adjuvant chemotherapy decisions, enabling more personalized and effective treatment. This investment reflects our commitment to supporting innovations that have a real-world impact on healthcare and patient outcomes. We look forward to seeing StratifAI lead the way in AI-driven oncology solutions. 🌍 Congratulations to the team! Omar El Nahhas, Firas Khader,Jakob Nikolas Kather, Daniel Truhn
We're thrilled to announce that StratifAI has raised €1.5M in pre-seed funding led by Neulogy Ventures and MultiplexDX International, with participation from Debiopharm, Arve Capital and Christoph Haarburger 🚀 With our diverse team of computer scientists and medical doctors, StratifAI builds the next generation of AI-based biomarkers to improve cancer patient outcomes 🧬 A huge thank you to our amazing investors, mentors and early supporters who believe in our vision. This is only the beginning! Check out the full press release below 👇 https://lnkd.in/gZj5uabH #precisiononcology #biomarkers #AI #cancer
-
🚀We are thrilled to announce our participation in Vivalyx €5M seed round alongside Brightlands Venture Partners, TVF | TechVision Fonds, GOOSE Capital, and esteemed business angels such as Springboard Health Angels, Angel Invest, Andrej Henkler, and others.🚀 Congratulation to Andreas Schumacher, Benedict Doorschodt, René H. Tolba, Christian Bleilevens and the entire Vivalyx team! 💪 Press release: 🫀 https://lnkd.in/erBaMcUy
Press Release: Vivalyx Closes Oversubscribed Seed Funding Round for the Clinical Study on Revitalization of Donor Organs
https://vivalyx.com